Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/12/2007 First Published: 5/1/1999


1.		Phase II Study of Recombinant Fowlpox Virus Encoding gp100 Peptide Preceded By an Endoplasmic Reticulum Insertion Signal in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-99-C-0044 NCI-T98-0088, T99-0088, NCT00019669

Last Modified: 5/31/2007 First Published: 6/1/1999


2.		Phase II Randomized Study of Recombinant Fowlpox Prostate Specific Antigen Vaccine and Recombinant Vaccinia Prostate Specific Antigen Vaccine in Patients With Advanced Prostate Cancer (Summary Last Modified 11/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				E-7897 NCT00003871, E7897

Last Modified: 5/31/2007 First Published: 7/1/1999


3.		Phase II Randomized Study of Recombinant Fowlpox and Vaccinia Viruses Encoding Tyrosinase Antigen in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-99-C-0095 NCI-T99-0025, T99-0025, NCT00019734

Last Modified: 12/3/2008 First Published: 5/28/2004


4.		Phase II Study of Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Comprising Fludarabine and Cyclophosphamide Followed By Autologous Lymphocyte Infusion, Recombinant Fowlpox Virus Encoding gp100 Peptide, and Aldesleukin in Patients With Recurrent or Refractory Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-04-C-0152 NCI-6585, 6585, NCT00084500

Last Modified: 1/1/1900


5.		Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18				NCI				NCI-95-C-0032D NCI-T96-0026N, T96-0026

Last Modified: 4/9/2003


6.		Phase I Study of Immunization With a Recombinant Fowlpox Virus Encoding the gp100 Melanoma Antigen With or Without Concurrent Interleukin-2 in Patients With Recurrent Metastatic Melanoma (Summary Last Modified 04/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-96-C-0121 NCI-T94-0139N, T94-0139, NCT00019175

Select All on One Page